HAE
Haemonetics Corp
$74.88
-0.14 (-0.19%)
At close · Jul 7
Market Cap
$3.40B
Shares
45,445,983
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.33B
-2%
FY2026
Net Income
$97.31K
-42%
FY2026
Gross Margin
59.04%
+4pp
FY2026
Operating Margin
11.75%
-4.6pp
FY2026
Diluted EPS
$2.05
-38.1%
FY2026
Operating Cash Flow
$293.22M
+61.4%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.46M | $988.48M | $967.58M | — | — | — | $910.37M | $938.51M | $891.99M | $727.84M | — | |
| — | $546.44M | $611.87M | $617.51M | $553.56M | $487.69M | $472.63M | $503.97M | $550.04M | $492.02M | $507.62M | $502.92M | $475.96M | $470.14M | $463.86M | $358.6M | $321.49M | |
| — | $787.59M | $748.96M | $691.55M | $615.1M | $505.5M | $397.84M | $484.51M | $417.54M | $411.91M | $378.49M | $405.91M | $434.42M | $468.37M | $428.13M | $369.24M | $355.21M | |
| — | 59.04% | 55.04% | 52.83% | 52.63% | 50.9% | 45.7% | 49.02% | 43.15% | — | — | — | 47.72% | 49.91% | 48% | 50.73% | — | |
| — | $59.77M | $62.72M | $54.44M | $50.13M | $46.8M | $32.86M | $30.88M | $35.71M | $39.23M | $37.56M | $44.97M | $54.19M | $54.2M | $44.39M | $36.8M | $32.66M | |
| — | $442.42M | $436.79M | $431.78M | $376.68M | $339.56M | $274.19M | $299.68M | $298.28M | $316.52M | $301.73M | $317.22M | $334.25M | $365.13M | $323.05M | $245.26M | $213.9M | |
| — | $50.5M | $55.6M | $41.4M | $42.1M | $56.6M | $32.83M | $34.2M | $32.6M | $31.9M | $37.2M | $59.3M | $33.5M | $29.2M | $22.1M | $11.4M | — | |
| — | $111.72M | $115.59M | $97.22M | $93.31M | $97.75M | $84.29M | $110.29M | $109.42M | $89.25M | $89.73M | $89.91M | $86.05M | $81.74M | $65.48M | $49.97M | $48.15M | |
| — | $3.11M | $13.91M | $14.09M | $657K | $4.23M | $1.44M | $3.59M | $395K | $30.53M | $21.83M | $23.06M | $36.86M | $49.05M | $10.89M | — | — | |
| — | $630.85M | $527.14M | $526.67M | $459.06M | $424.75M | $308.09M | $381.16M | $333.99M | $355.75M | $397.88M | $449.86M | $393.88M | $421.04M | $371.69M | $280.48M | $244.66M | |
| — | $156.73M | $221.82M | $164.88M | $156.03M | $80.75M | $89.75M | $103.35M | $83.55M | $56.16M | -$19.38M | -$43.94M | $40.54M | $47.33M | $56.44M | $88.76M | $110.55M | |
| — | 11.75% | 16.3% | 12.6% | 13.35% | 8.13% | 10.31% | 10.46% | 8.63% | — | — | — | 4.45% | 5.04% | 6.33% | 12.19% | — | |
| — | $268.45M | $337.4M | $262.1M | $249.34M | $178.5M | $174.03M | $213.64M | $192.96M | $145.4M | $70.35M | $45.97M | $126.59M | $129.07M | $121.92M | $138.72M | $158.69M | |
| -$41K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $6000 | |
| $388K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $384K | |
| — | -$28.7M | -$9.75M | -$13.02M | -$14.63M | -$17.12M | -$16.83M | -$16.2M | -$9.91M | -$4.53M | -$8.1M | -$9.47M | -$9.38M | -$10.93M | -$6.54M | $740K | -$845K | |
| $0 | — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $128.03M | $212.07M | $151.87M | $141.4M | $63.63M | $72.91M | $87.15M | $73.63M | $59.63M | -$27.48M | -$53.42M | $31.17M | $36.4M | $49.9M | $89.5M | $110.08M | |
| — | $30.72M | $44.39M | $34.31M | $26M | $20.25M | -$6.56M | $10.63M | $18.61M | $14.06M | -$1.21M | $2.16M | $14.27M | $1.25M | $11.1M | $22.61M | $30.1M | |
| — | $97.31K | $167.68K | $117.56M | $115.4M | $43.38M | $79.47M | $76.53M | $55.02M | $45.57M | -$26.27M | -$55.58M | $16.9M | $35.15M | $38.8M | $66.89M | $79.98M | |
| — | 0.01% | 0.01% | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | — | — | — | 1.86% | 3.75% | 4.35% | 9.19% | — | |
| — | $114.78M | $148.23M | $112.31M | $110.97M | $46.97M | $95.06M | $61.77M | $43.63M | $59.45M | -$24.1M | -$68.9M | -$6.24M | $31.13M | $35.12M | -$431K | — | |
| USD/shares | — | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 | $0.86 | -$0.51 | -$1.09 | $0.33 | $0.68 | $0.76 | $2.64 | $3.19 |
| USD/shares | — | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | -$0.51 | -$1.09 | $0.32 | $0.67 | $0.74 | $2.59 | $3.12 |
| shares | — | 47.18M | 50.33M | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.52M | 50.91M | 51.53M | 51.61M | 51.35M | 25.36M | 25.08M |
| shares | — | 47.35M | 50.73M | 51.4M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.5M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 25.8M | 25.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2026: $1.16B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 3.70×
EV/EBIT
—
Medical Devices median 21.44×
P/E (TTM)
36.53×
Medical Devices median 26.54×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 |
|---|---|---|---|---|---|
| Hospital | $588,304,000 | $564,269,000 | $456,289,000 | $381,710,000 | — |
| Plasma | $524,456,000 | $535,431,000 | $569,535,000 | $499,916,000 | — |
| Blood Center | $221,267,000 | $261,124,000 | $283,231,000 | $287,034,000 | — |
| Business Unit | — | — | — | — | $972,663,000 |
By Geography (USD)
| Component | 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | 2021-04-03 | 2020-03-28 | 2019-03-30 |
|---|---|---|---|---|---|---|---|---|
| United States | $982,176,000 | $1,010,918,000 | $970,007,000 | $842,897,000 | $639,322,000 | $522,607,000 | $646,204,000 | $606,845,000 |
| Europe | $185,019,000 | $175,655,000 | $160,142,000 | $156,680,000 | $163,520,000 | $159,077,000 | $153,347,000 | $164,504,000 |
| Asia | $87,212,000 | $92,305,000 | $107,536,000 | $104,135,000 | $110,802,000 | $105,820,000 | $109,295,000 | $118,700,000 |
| Japan | $68,200,000 | $62,408,000 | $58,087,000 | $61,295,000 | $75,562,000 | $77,676,000 | $72,218,000 | $69,908,000 |
| Other Country or Region | $11,420,000 | $19,538,000 | $13,283,000 | $3,653,000 | $3,990,000 | $5,283,000 | $7,415,000 | $7,622,000 |
By Product & Service (USD)
| Component | 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | 2021-04-03 | 2020-03-28 | 2019-03-30 |
|---|---|---|---|---|---|---|---|---|
| Hospital Products and Services | $588,304,000 | $564,269,000 | $456,289,000 | — | — | — | — | — |
| Blood Center Products and Services | $221,267,000 | $261,124,000 | $283,231,000 | — | — | — | — | — |
| Blood Center | — | — | — | $226,819,000 | $236,158,000 | $239,614,000 | $252,829,000 | $269,203,000 |
| Hospital | — | — | — | $378,107,000 | $329,427,000 | $216,583,000 | $198,419,000 | $196,539,000 |
| Plasma | — | — | — | $563,734,000 | $427,611,000 | $414,266,000 | $537,231,000 | $501,837,000 |
| Service | — | — | $21,605,000 | $20,044,000 | $20,533,000 | $20,758,000 | $19,830,000 | $19,906,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | 2021-04-03 | 2020-03-28 | 2019-03-30 |
|---|---|---|---|---|---|---|---|---|
| Plasma | $184,795,000 | $184,510,000 | $181,967,000 | $124,746,000 | $183,131,000 | $172,463,000 | $225,351,000 | $180,300,000 |
| Hospital | $103,735,000 | $88,975,000 | $52,198,000 | $29,415,000 | $129,783,000 | $84,066,000 | $80,669,000 | — |
| Blood Center | $49,976,000 | $52,819,000 | $42,372,000 | $64,272,000 | $136,691,000 | $141,962,000 | $159,802,000 | $163,628,000 |
| Japan | — | — | — | — | — | — | $225,351,000 | $180,300,000 |
| Americas Blood Centerand Hospitaland Asia Pacific | — | — | — | — | — | $84,066,000 | $80,669,000 | $76,338,000 |
| EMEA | — | — | — | — | — | — | $159,802,000 | $163,628,000 |
Operating Margin by Segment (%)
| Component | 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 |
|---|---|---|---|---|
| Hospital | 17.6% | 15.8% | 11.4% | 7.7% |
| Plasma | 35.2% | 34.5% | 32% | 25% |
| Blood Center | 22.6% | 20.2% | 15% | 22.4% |